Factors Associated with Seeking and Receiving Home Antiviral Therapy During the COVID-19 Pandemic.

ABSTRACT:

Background

Home antiviral treatment (HAVT: nirmatrelvir/ritonavir [Paxlovid] and molnupiravir [Lagevrio]) for COVID-19 was approved in December 2021 by the U.S. Food and Drug Administration, but ensuing utilization during the COVID-19 pandemic was low. Factors associated with seeking HAVT treatment have not been fully explored.

Study design

Cross-sectional survey of 9,944 U.S. adults to identify factors associated with seeking and receiving HAVT in persons with confirmed or suspected COVID-19.

Results

COVID-19 infection was confirmed or suspected in 4,355 (43.8%) participants. HAVT was sought by 1,331 (26.3%) and medication was received by 928 (20.7%). In comparison to those who were COVID-19 test negative and had no loss of taste or smell (aOR: 1.856, 95% C.I.: 1.262

SUBMITTER: Quan SF 

PROVIDER: S-EPMC12148280 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature